AI Bio Deal Wave

OpenAI's acquisition validates life sciences as a priority market for frontier AI companies and accelerates partnership activity across pharma, clinical-data platforms, and AI-drug-discovery firms. This scenario produces the strongest sector read-through, though it remains an industry-level reaction rather than a macro shock.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.